Navigation Links
Merck Serono Announces Initiation of the ORACLE MS Trial to Evaluate Cladribine Tablets in Patients at Risk of Developing Multiple Sclerosis
Date:9/17/2008

definite multiple sclerosis."

"As a leader in multiple sclerosis treatments, we are committed to providing new options that can further improve the course of the disease and the quality of life for people living with this disease," said Dr. Richard Douge, Executive Vice President, Global Marketing, Merck Serono. "The initiation of the ORACLE MS study further demonstrates our commitment to continue to build a solid portfolio of products for use in a broad multiple sclerosis patient population. We believe that our proprietary oral formulation of Cladribine has the potential to address an important unmet medical need at a critical time of disease development."

The ORACLE MS study is a randomized, double-blind, placebo-controlled, international trial. It will involve more than 600 patients considered at risk of developing MS due to a recently experienced isolated demyelinating event (e.g. optic neuritis, myelopathy or brainstem syndrome) and having MRI brain scans consistent with early signs of MS. Study participants will be randomized in one of the three arms of the study to receive one of two different dosage regimens of Cladribine tablets or matching placebo tablets (1:1:1 ratio).

Patients will be treated for a period of two years (96 weeks), or up to the time when they experience a second attack leading to a diagnosis of clinically definite MS, in which case they would be offered open-label treatment with Rebif(R) 44 mcg three times a week for a 96-week maintenance treatment period. Patients who do not convert to clinically definite MS within the initial 96-week period of the study will be eligible to enroll in a 96- week long-term follow-up treatment period. These maintenance and long-term follow-up periods of the study are intended to assess the effect of early treatment with Cladribine tablets on relapses and subsequent treatment response to disease-modifying therapy for relapsing-remitting MS and to evaluate the sustained effect of Cladribi
'/>"/>

SOURCE Merck Serono International S A
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Merck/Gilead Once-A-Day AIDS Pill Not Available in Most Places - AHF Urges Speed-Up of Registrations
2. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
3. MJFF and Merck Serono (EMD Serono in North America) Join Forces on $2-Million Initiative to Drive Treatments for PD-Related Cognitive Dysfunction and Mood Disorders
4. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
5. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
6. Microbicide Developer Receives License for Novel HIV Microbicide Candidate From Merck & Co., Inc.
7. Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch
8. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
9. MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc.
10. Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc.
11. Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015  Today, in final ... (CDC) Contact Lens Health Week, 1-800 Contacts is sharing ... found that contact lens wearers who do not properly ... risk for eye infections. Most contact ... lenses, but a clean lens case is sometimes overlooked.  ...
(Date:8/28/2015)... Aug. 28, 2015 Research ... of the "Investigation Report on China,s Ranibizumab Market, ... by Novartis, ranibizumab was approved by CFDA to treat ... only Lucentis, a product of Novartis, is available in ... first self- developed drug for the treatment of wet ...
(Date:8/28/2015)... , FARUM, Denmark and ... On July 31, 2015 the US Food and Drug Administration ... of Major Depressive Disorder in adult patients who have failed ... current episode. TMS is a non-invasive technique for stimulating neural ... suffering from Major Depressive Disorder. The procedure has been proven ...
Breaking Medicine Technology:1-800 Contacts Shares Tips on How to Clean Lens Cases 2Investigation Report on China's Ranibizumab Market, 2012-2019 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3
... March 16, 2011 Unilife Corporation ("Unilife" or the "Company") ... its Chief Executive Officer, Alan Shortall, has made open market ... the Australian Stock Exchange (ASX). Mr. Shortall, who ... 632,713 CDIs at an average price of A$0.795 (US$0.80) per ...
... /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, ... CMED ), a leading ... company, today announced that it ... following investor conferences and events: ...
Cached Medicine Technology:Unilife CEO Makes Open Market Purchase of A$500,000 in Company's Publicly Traded Shares 2Unilife CEO Makes Open Market Purchase of A$500,000 in Company's Publicly Traded Shares 3China Medical Technologies to Meet Investors 2
(Date:8/28/2015)... ... August 28, 2015 , ... With the goal of ... for the second year to the Adams County Fairgrounds in Mendon, IL on May ... raise money to support music education in the underfunded school districts of Mendon and ...
(Date:8/28/2015)... ... August 28, 2015 , ... The 6th Annual Survivor ... Aneurysm Foundation has added yet another accolade to its cadre of widespread support—an official ... , “With the help of the medical community and the University of Illinois at ...
(Date:8/28/2015)... ... ... “ Frequentz ” was featured on NewsWatch as part of its monthly ... for iOS, Android, and Windows. Joe Toohey, the host of AppWatch and technology expert, ... track product movement from beginning to end. , Businesses benefit greatly from having the ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Nashville Business Journal recently ... in business. Mr. Troy Mizell, Chairman of the Board at MyGenetx, is ... 2015 Veterans Awards will recognize Nashville military veterans who, through their professional and ...
(Date:8/28/2015)... Rochester, NY (PRWEB) , ... August 28, 2015 , ... ... injectable, Kybella™. It is the first and only nonsurgical product approved by the ... Dr. Vito Quatela and Dr. William Koenig are among ...
Breaking Medicine News(10 mins):Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Track Product Movement from Beginning to End with Frequentz 2Health News:MyGenetx Board Member Receives Veterans Award 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3
... CEPH ) announced today that the underwriters ... aggregate principal amount of 2.50% convertible senior subordinated notes ... to purchase $65 million of additional notes, bringing the ... $500 million. Completion of the notes offering, including the ...
... Ontario Systems, a leading provider of revenue cycle ... management and health care industries, today announced that ... the company and will lead its debt management ... direction of all Ontario debt management solutions, including ...
... tied to this nutritional deficit , , FRIDAY, May ... may contribute to cancer development, U.S. researchers have found. ... communication among cells due to, among other things, low ... an epidemiologist at the Moores Cancer Center at the ...
... findings could alter treatment methods, , , THURSDAY, May 21 (HealthDay ... amputated because of diabetes were reduced by 36 percent when ... to lower their blood fat levels, new research has found. ... who took either 200 milligrams of fenofibrate or a placebo ...
... Patients under 44 were three times more likely to die, ... Younger men diagnosed with advanced prostate cancer don,t live as ... study finds. , "Overall, young men with prostate cancer do ... prostate cancers did substantially worse than old men with similar ...
... May 22 The National Board of Certification for ... performance exam that will be part of the testing ... weeks, 300 interpreters will "test the test" designed to ... and skills in real-life medical interpreting scenarios. This process ...
Cached Medicine News:Health News:Cephalon Announces Exercise of $65 Million Over-allotment Option on 2.50% Convertible Senior Subordinated Notes 2Health News:Cephalon Announces Exercise of $65 Million Over-allotment Option on 2.50% Convertible Senior Subordinated Notes 3Health News:Cephalon Announces Exercise of $65 Million Over-allotment Option on 2.50% Convertible Senior Subordinated Notes 4Health News:Cutler to Direct Debt Management Product Strategy at Ontario Systems 2Health News:Drug May Lessen Amputation Risk for Diabetics 2Health News:Advanced Prostate Cancer Deadlier in Younger Men 2Health News:Advanced Prostate Cancer Deadlier in Younger Men 3Health News:National Medical Interpreter Certification Testing Enters Pilot Phase 2Health News:National Medical Interpreter Certification Testing Enters Pilot Phase 3
Desmarres Lid Retractor thin solid blades. Size 2....
... of the AMO Prestige System marked ... The combination of safety with high-performance ... of fluidic conditions in the in ... Pump" orchestrates the reaction and interaction ...
Highly versatile, efficient, compact and accurate digital readout display....
... phaco system has all the features of ... dependable engineering means minimal maintenance. Small, light ... site to site. Lowest cost reusable tubing ... No longer is there a price objection ...
Medicine Products: